1492 Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-7,683
| Closed | -$501K | – | 114 |
|
|
2025
Q2 | $501K | Sell |
7,683
-200
| -3% | -$13K | 0.23% | 77 |
|
|
2025
Q1 | $528K | Sell |
7,883
-295
| -4% | -$17.6K | 0.28% | 69 |
|
|
2024
Q4 | $452K | Hold |
8,178
| – | – | 0.22% | 73 |
|
|
2024
Q3 | $488K | Hold |
8,178
| – | – | 0.24% | 60 |
|
|
2024
Q2 | $521K | Hold |
8,178
| – | – | 0.29% | 60 |
|
|
2024
Q1 | $565K | Sell |
8,178
-10,000
| -55% | -$604K | 0.31% | 65 |
|
|
2023
Q4 | $1M | Hold |
18,178
| – | – | 0.57% | 63 |
|
|
2023
Q3 | $1.06M | Hold |
18,178
| – | – | 0.68% | 53 |
|
|
2023
Q2 | $979K | Hold |
18,178
| – | – | 0.57% | 59 |
|
|
2023
Q1 | $722K | Hold |
18,178
| – | – | 0.45% | 66 |
|
|
2022
Q4 | $731K | Hold |
18,178
| – | – | 0.47% | 62 |
|
|
2022
Q3 | $584K | Hold |
18,178
| – | – | 0.42% | 73 |
|
|
2022
Q2 | $539K | Hold |
18,178
| – | – | 0.35% | 77 |
|
|
2022
Q1 | $511K | Sell |
18,178
-25,433
| -58% | -$948K | 0.27% | 75 |
|
|
2021
Q4 | $2.01M | Buy |
43,611
+25,433
| +140% | +$1.09M | 0.99% | 38 |
|
|
2021
Q3 | $597K | Hold |
18,178
| – | – | 0.3% | 74 |
|
|
2021
Q2 | $637K | Hold |
18,178
| – | – | 0.33% | 72 |
|
|
2021
Q1 | $657K | Sell |
18,178
-5,355
| -23% | -$168K | 0.37% | 60 |
|
|
2020
Q4 | $683K | Sell |
23,533
-1,470
| -6% | -$42.1K | 0.39% | 63 |
|
|
2020
Q3 | $705K | Sell |
25,003
-67
| -0.3% | -$2K | 0.53% | 51 |
|
|
2020
Q2 | $811K | Hold |
25,070
| – | – | 0.69% | 43 |
|
|
2020
Q1 | $1.02M | Sell |
25,070
-23
| -0.1% | -$1.22K | 1.22% | 23 |
|
|
2019
Q4 | $1.55M | Sell |
25,093
-88
| -0.3% | -$5.83K | 1.37% | 23 |
|
|
2019
Q3 | $1.83M | Hold |
25,181
| – | – | 1.79% | 19 |
|
|
2019
Q2 | $2.07M | Sell |
25,181
-510
| -2% | -$36.3K | 1.94% | 15 |
|
|
2019
Q1 | $1.81M | Sell |
25,691
-3,050
| -11% | -$179K | 1.53% | 22 |
|
|
2018
Q4 | $1.29M | Sell |
28,741
-845
| -3% | -$44.3K | 1.16% | 28 |
|
|
2018
Q3 | $1.67M | Sell |
29,586
-2,050
| -6% | -$125K | 1.09% | 32 |
|
|
2018
Q2 | $2.11M | Sell |
31,636
-4,685
| -13% | -$292K | 1.51% | 27 |
|
|
2018
Q1 | $2.12M | Buy |
36,321
+972
| +3% | +$61.7K | 1.63% | 24 |
|
|
2017
Q4 | $2.28M | Sell |
35,349
-8,018
| -18% | -$499K | 1.78% | 23 |
|
|
2017
Q3 | $2.28M | Sell |
43,367
-14
| -0% | -$668 | 2.01% | 17 |
|
|
2017
Q2 | $2.03M | Sell |
43,381
-227
| -0.5% | -$11K | 1.79% | 20 |
|
|
2017
Q1 | $2.16M | Buy |
43,608
+1,010
| +2% | +$56.7K | 1.68% | 26 |
|
|
2016
Q4 | $2.58M | Buy |
42,598
+8,098
| +23% | +$495K | 1.99% | 22 |
|
|
2016
Q3 | $2.29M | Buy |
+34,500
| New | +$2.16M | 1.87% | 24 |
|
Other funds holding ANIP
GACM
DTC
1492 Capital Management's ANIP Position: Q3 2025 in Review
1492 Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q3 2025, closing a stake of 7,683 shares — an estimated $501K sold.
1492 Capital Management first reported a position in ANIP in Q3 2016 and held it in 36 quarters. The position peaked at $2.58M in Q4 2016. 269 funds tracked by Wall St. Rank hold ANIP as of Q3 2025.
- 1492 Capital Management reported no remaining ANI Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
- 1492 Capital Management sold 7,683 ANI Pharmaceuticals shares in Q3 2025, an estimated $501K.
- 1492 Capital Management first reported a position in ANI Pharmaceuticals in Q3 2016 and held it in 36 quarters.
- 1492 Capital Management's ANI Pharmaceuticals position peaked at $2.58M in Q4 2016.
- 269 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2025.
Based on 1492 Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.